PRECIGEN, INC. Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent
PRECIGEN, INC. (PGEN) had Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent of $0 as of 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent · last filed 2023-03-06
- 2022-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent $0.00.
- 2022-09-30: Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent $0.00.
- 2022-06-30: Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent $3.62M.
- 2021-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent $3.67M.
| Period end | Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent | Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent as first filed |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.62M 10-Q · filed 2022-08-08 | |
| 2021-12-31 | $3.67M 10-K · filed 2023-03-06 | |
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |
| 2019-12-31 | $13.73M 10-K · filed 2021-03-01 | $0.00 10-K · filed 2020-03-02 |
| 2018-12-31 | $10.96M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |